Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.3.0.814
Consolidated Statements of Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Operating costs and expenses:        
Research and development $ (816,318) $ (1,905,234) $ (2,407,141) $ (3,502,805)
General and administrative (2,984,484) (1,203,126) (4,723,109) (5,204,541)
Loss from operations (3,800,802) (3,108,360) (7,130,250) (8,707,346)
Other income (expense):        
Change in fair value of derivative liability (1,344,542) 0 (1,344,542) 0
Loss on disposal of subsidiaries 0 0 0 (1,069,675)
Other expense (50,526) (72,877) (276,041) (235,484)
Interest income 67 218 1,155 11,960
Interest expense (127,896) (1,196) (130,408) (3,569)
Total other income (expense) (1,522,897) (73,855) (1,749,836) (1,296,768)
Net loss (5,323,699) (3,182,215) (8,880,086) (10,004,114)
Other comprehensive income (loss) from foreign currency translation adjustment 5,112 (542,098) (321,942) (18,457)
Total comprehensive loss $ (5,318,587) $ (3,724,313) $ (9,202,028) $ (10,022,571)
Net loss per share of common stock, basic and diluted $ (.04) $ (.02) $ (.06) $ (.07)
Weighted-average shares of common stock outstanding, basic and diluted 139,618,390 136,052,498 139,405,494 134,749,810